277 related articles for article (PubMed ID: 10834273)
1. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
[TBL] [Abstract][Full Text] [Related]
2. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
3. Strategies for enzyme/prodrug cancer therapy.
Xu G; McLeod HL
Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
[TBL] [Abstract][Full Text] [Related]
4. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
Connors TA
Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
[TBL] [Abstract][Full Text] [Related]
5. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
6. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
Khatri A; Russell PJ
Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
[TBL] [Abstract][Full Text] [Related]
7. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
8. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
Greco O; Dachs GU
J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
[TBL] [Abstract][Full Text] [Related]
9. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.
Schepelmann S; Hallenbeck P; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Hay C; Hawkins LK; Marais R; Springer CJ
Cancer Res; 2005 Jun; 65(12):5003-8. PubMed ID: 15958540
[TBL] [Abstract][Full Text] [Related]
10. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.
Syrigos KN; Epenetos AA
Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606
[TBL] [Abstract][Full Text] [Related]
11. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy.
Mancini L; Davies L; Friedlos F; Falck-Miniotis M; Dzik-Jurasz AS; Springer CJ; Leach MO; Payne GS
NMR Biomed; 2009 Jun; 22(5):561-6. PubMed ID: 19259950
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
13. Prodrug activation enzymes in cancer gene therapy.
Aghi M; Hochberg F; Breakefield XO
J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
Both GW
Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
[TBL] [Abstract][Full Text] [Related]
17. Prodrug strategies in anticancer chemotherapy.
Kratz F; Müller IA; Ryppa C; Warnecke A
ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
[TBL] [Abstract][Full Text] [Related]
18. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
[TBL] [Abstract][Full Text] [Related]
19. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
20. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
Bagshawe KD
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1421-31. PubMed ID: 17069527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
